United States Biotechnology & Medical Research

BIOAGE Labs Inc (BIOA)

Track

Over the past 90 days, BIOAGE Labs Inc. has seen exclusively insider selling activity, totaling approximately $3.15 million in value. These transactions were primarily planned sales executed by company officers. This activity follows the company's recent earnings report in May, during which the stock price has experienced a 32.2% increase over the last quarter.
Ticker: BIOA
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for BIOAGE Labs Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 30 Jun 2026
Value US$3,857,487.42 | Price 471.54 | Shares 73,643 (+14.5%)
Proposed sale 30 Jun 2026
Value US$1,227,849.18 | Price 146.32 | Shares 95,878
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-01 2026-06-30 PlS Planned sale
Barton Shane

Principal Accounting Officer

Officer
73,643 +14.5%
471.54
US$3,857,487 		73,643 +14.5% 471.54 US$3,857,487
2026-06-30 2026-06-30 PrS Proposed sale
Barton Shane

Officer

Officer
95,878
146.32
US$1,227,849 		95,878 146.32 US$1,227,849
2026-07-01 2026-06-29 PlS Planned sale
Barton Shane

Principal Accounting Officer

Officer
20,027 -32.3%
372.48
US$4,436,827 		20,027 -32.3% 372.48 US$4,436,827
2026-06-29 2026-06-29 PrS Proposed sale
Barton Shane

Officer

Officer
42,350
25.21
US$1,067,578 		42,350 25.21 US$1,067,578
2026-04-03 2026-04-01 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
8,820 -100.0%
17.81
US$157,084 		8,820 -100.0% 17.81 US$157,084
2026-04-03 2026-04-01 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
8,820 -100.0%
17.81
US$157,084 		8,820 -100.0% 17.81 US$157,084
2026-04-01 2026-04-01 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
8,820
17.81
US$157,084 		8,820 17.81 US$157,084
2026-03-03 2026-03-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
20.30
US$150,890 		7,433 -100.0% 20.30 US$150,890
2026-03-02 2026-03-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
20.03
US$148,883 		7,433 20.03 US$148,883
2026-02-03 2026-02-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
18.75
US$139,369 		7,433 -100.0% 18.75 US$139,369
2026-02-03 2026-02-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
18.75
US$139,369 		7,433 -100.0% 18.75 US$139,369
2026-02-02 2026-02-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
18.75
US$139,369 		7,433 18.75 US$139,369
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
1,923 -7.9%
21.08
US$40,538 		1,923 -7.9% 21.08 US$40,538
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
11,663 -32.4%
20.54
US$239,549 		11,663 -32.4% 20.54 US$239,549
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
4,440 -11.0%
19.45
US$86,370 		4,440 -11.0% 19.45 US$86,370
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
8,974 -18.2%
18.43
US$165,371 		8,974 -18.2% 18.43 US$165,371
2026-01-15 2026-01-13 PlS Planned sale
Fortney Kristen

Chief Executive Officer

Executive Director
233,107 -19.3%
18.12
US$4,223,036 		233,107 -19.3% 18.12 US$4,223,036
2026-01-13 2026-01-13 PrS Proposed sale
Fortney Kristen

10% Stockholder

Large shareholder
233,107
18.00
US$4,195,926 		233,107 18.00 US$4,195,926
2026-01-13 2026-01-13 PrS Proposed sale
0.6
GOLDSTEIN DOV A MD

Officer

Officer
27,000
19.70
US$531,828 		27,000 19.70 US$531,828
2026-01-06 2026-01-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
12.85
US$95,490 		7,433 -100.0% 12.85 US$95,490
2026-01-02 2026-01-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
13.41
US$99,677 		7,433 13.41 US$99,677
2025-12-11 2025-12-09 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
18,000 -100.0%
12.00
US$216,000 		18,000 -100.0% 12.00 US$216,000
2025-12-09 2025-12-09 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
18,000
12.00
US$216,000 		18,000 12.00 US$216,000
2025-12-05 2025-12-04 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
68,897 -100.0%
10.19
US$701,909 		68,897 -100.0% 10.19 US$701,909
2025-12-04 2025-12-04 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
68,897
10.19
US$701,912 		68,897 10.19 US$701,912
2024-10-03 2024-10-03 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
25,306 +2.3%
19.90
US$503,589 		25,306 +2.3% 19.90 US$503,589
2024-10-03 2024-10-02 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
67,096 +6.5%
19.73
US$1,323,804 		67,096 +6.5% 19.73 US$1,323,804
2024-10-03 2024-10-01 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
126,793 +14.1%
19.73
US$2,501,626 		126,793 +14.1% 19.73 US$2,501,626
2025-03-10 2024-09-27 B Purchase
Barton Shane

Principal Accounting Officer

Officer
2,632 +inf%
18.00
US$47,376 		2,632 +inf% 18.00 US$47,376
2024-10-01 2024-09-27 B Purchase
3.7
Cormorant Asset Management, LP

Former 10% Owner
450,000 +38.2%
18.00
US$8,100,000 		450,000 +38.2% 18.00 US$8,100,000
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
26,497 +inf%
18.00
US$476,946 		26,497 +inf% 18.00 US$476,946
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
21,814 +inf%
18.00
US$392,652 		21,814 +inf% 18.00 US$392,652
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
18,353 +inf%
18.00
US$330,354 		18,353 +inf% 18.00 US$330,354
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
11,113 +inf%
18.00
US$200,034 		11,113 +inf% 18.00 US$200,034
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
588,888 +35.9%
18.00
US$10,599,984 		588,888 +35.9% 18.00 US$10,599,984
2024-09-27 2024-09-27 B Purchase
3.6
ENRIGHT PATRICK G
Non-Executive Director
400,000 +30.5%
18.00
US$7,200,000 		400,000 +30.5% 18.00 US$7,200,000
2024-09-27 2024-09-27 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
900,000 +inf%
18.00
US$16,200,000 		900,000 +inf% 18.00 US$16,200,000
Explore more

More insider trading research around BIOAGE Labs Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America